$34.07
▼ -2.0% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating
Overview
52-week range
$19
$36
90% of range
Avg surprise (last 3)
-4.7%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
53%
EM ±12.0% · $34 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-1.18 | $-1.10 | -7.3% | -45.7% | -3.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.01 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.85 | $-0.86 | +1.2% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.81 | $-0.75 | -8.0% | — | +3.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.64 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.54 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.56 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.81 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.65 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$1.04 | -$0.85 | -22.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-84M | — | $-74M | $-64M | $-63M | — | $-52M | $-46M |
| Net income | $-79M | — | $-67M | $-57M | $-54M | — | $-42M | $-36M |
| EPS (diluted) | $-1.18 | — | $-1.01 | $-0.85 | $-0.81 | — | $-0.64 | $-0.54 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36M | $29M | $36M | $23M | $17M | $28M | $36M | $43M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $459M | $535M | $604M | $648M | $694M | $747M | $779M | $812M |
| Total assets | $511M | $583M | $648M | $692M | $739M | $792M | $823M | $846M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $55M | $56M | $50M | $37M | $36M | $45M | $37M | $32M |
| Total equity | $456M | $527M | $598M | $655M | $703M | $747M | $786M | $814M |